Results 21 to 30 of about 54,328 (210)

Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists [PDF]

open access: yesClinical Parkinsonism & Related Disorders, 2021
Dopamine agonists are one of the main stay of treatment option for Parkinson disease (PD). Side effects that develop from their use are generally categorized into behavioral and non-behavioral.
Mohammad Edrees Mohammad   +6 more
doaj   +2 more sources

From Selye’s and Szabo’s Cysteamine-Duodenal Ulcer in Rats to Dopamine in the Stomach: Therapy Significance and Possibilities

open access: yesPharmaceuticals, 2023
We reviewed gastric ulcer healing by dopamine considering several distinctive duodenal key points. Selye and Szabo describe the cysteamine-induced duodenal ulcer in rats as a duodenal stress ulcer in patients.
Predrag Sikiric   +24 more
doaj   +1 more source

Observations on sleep-disordered breathing in idiopathic Parkinson's disease. [PDF]

open access: yesPLoS ONE, 2014
BACKGROUND: This study has two main goals: 1.) to determine the potential influence of dopaminergic drugs on sleep-disordered breathing (SDB) in Parkinson's disease (PD) and 2.) to elucidate whether NREM and REM sleep differentially impact SDB severity ...
Philipp O Valko   +4 more
doaj   +1 more source

Resistance to dopamine agonists in the treatment of prolactinomas: diagnostic criteria, mechanisms and ways to overcome it

open access: yesAlʹmanah Kliničeskoj Mediciny, 2023
The priority treatment approach for prolactinomas is therapy with dopamine agonists, which allows for elimination of clinical symptoms, normalization of prolactin levels, reduction of the adenoma size and prevention of metabolic abnormalities in the ...
Irena A. Ilovayskaya, Gulnar R. Vagapova
doaj   +1 more source

Dopamine agonists and antipsychotics [PDF]

open access: yesEuropean Journal of Endocrinology, 2020
There can potentially be a number of clinical interactions that could adversely affect patient outcomes in a patient with a prolactinoma and psychiatric disease that might require antipsychotic and dopamine agonist treatment. Dopamine agonists stimulate the dopamine D2 receptor, resulting in a decrease in prolactin (PRL) levels and in prolactinoma size
openaire   +2 more sources

Adsorption properties of dopamine derivatives using carbon nanotubes: A first-principles study [PDF]

open access: yesApplied Surface Science, Volume 501, 31 January 2020, 144249, 2020
Detecting dopamine is of great biological importance because the molecule plays many roles in the human body. For instance, the lack of dopamine release is the cause of Parkinson's disease. Although many researchers have carried out experiments on dopamine detection using carbon nanotubes (CNTs), there are only a few theoretical studies on this topic ...
arxiv   +1 more source

Predictors of dopamine agonist resistance in prolactinoma patients

open access: yesBMC Endocrine Disorders, 2020
Background Surgical resection of prolactinomas resistant to dopamine agonists is frequently incomplete due to fibrotic changes of the tumour under pharmacological therapy. In order to identify a subgroup of patients who may benefit from early surgery, we
Elle Vermeulen   +6 more
doaj   +1 more source

Clinical Aspects and Management of Levodopa-Induced Dyskinesia

open access: yesParkinson's Disease, 2012
In Parkinson's disease, one of the most troublesome dilemmas is the treatment of levodopa-induced dyskinesia. After a few years, chronic treatment with levodopa is associated with the development of dyskinesias.
Nicola Tambasco   +7 more
doaj   +1 more source

Rapid quantitative pharmacodynamic imaging by a novel method: theory, simulation testing and proof of principle [PDF]

open access: yesPeerJ 1:e117, 2013, 2013
Pharmacological challenge imaging has mapped, but rarely quantified, the sensitivity of a biological system to a given drug. We describe a novel method called rapid quantitative pharmacodynamic imaging. This method combines pharmacokinetic-pharmacodynamic modeling, repeated small doses of a challenge drug over a short time scale, and functional imaging
arxiv   +1 more source

Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma

open access: yesJournal of Investigative Medicine High Impact Case Reports, 2021
Dopamine agonists are generally well tolerated and represent the first-line therapy for prolactinomas. We report a case of a 20-year-old man with a macroprolactinoma who developed recurrent priapism with cabergoline and bromocriptine.
Lakshmi P. Menon MD, Wedad Rahman MD
doaj   +1 more source

Home - About - Disclaimer - Privacy